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Background: To estimate cardiovascular disease (CVD) mortality in relation to obesity and gender.
Methods: Data from 11 prospective cohorts from four European countries including 23 629 men and 21 965 women,
aged 24 to 99 years, with a median follow-up of 7.9 years were analyzed. Hazards ratios (HR) for CVD mortality in relation
to baseline body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR)
were estimated using Cox proportional hazards models with age as the timescale.
Results: Men had higher CVD mortality than women in all four BMI categories (<25.0, 25.0-29.9, 30.0-34.9 and ≥35.0 kg/m2).
Compared with the lowest BMI category in women, multivariable adjusted HRs (95% confidence intervals) for higher
BMI categories are 1.0 (0.8-1.4), 1.6 (1.1-2.1) and 2.8 (2.0-3.8) in women and 2.8 (2.2-3.6), 3.1 (2.5-3.9), 3.8 (2.9-4.9) and 5.4
(3.8-7.7) in men, respectively. Similar findings were observed for abdominal obesity defined by WC, WHR or WHtR. The
gender difference was slightly smaller in obese than in non-obese individuals; but the interaction was statistically
significant only between gender and WC (p = 0.02), and WHtR (p = 0.01). None of the interaction terms was significant
among non-diabetic individuals.
Conclusions: Men had higher CVD mortality than women across categories of anthropometric measures of obesity.
The gender difference was attenuated in obese individuals, which warrants further investigation.
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Cardiovascular diseases (CVD) are still the leading cause
of mortality in both men and women [1]. Further, women
are known to have a much lower risk for CVD mortality
than men. There is substantial evidence of a gender differ-
ence in cardiac autonomic modulation [2-5], lipid and
glucose metabolism [6-9], sex hormones [4,10-14] and
cytokines [15-19]. On average, women would have aug-
mented sympathetic inhibition, higher cardiac vagal tone,
higher heart rate variability, lower susceptibility to ar-
rhythmias, and decreased myocardial contractility than
men [2,3,20], leading to a preponderance of vagal over
sympathetic control of cardiac function [2-5]. Moreover,* Correspondence: xin.song@helsinki.fi
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and LDL-C), triglycerides and apolipoprotein B and higher
levels of high-density lipoprotein cholesterol (HDL-C) and
apolipoprotein A-I than their male counterparts [6,21-23]
although TC and LDL-C increase in women after meno-
pause [21,22]. However, this female advantage is abrogated
with diabetes and aging [24-32], perhaps as a consequence
of diabetes inducing higher levels of inflammatory mar-
kers and higher rates of nitric oxide release in women
compared with men, resulting in reduced protective ef-
fects of estrogen on body fat distribution and insulin
action, or a more impaired endothelial function in women
than in men [10,33]. The prevalence of obesity is rising
worldwide, leading to an increased risk for diabetes and
CVD [34,35]. It is not clear, however, whether the gendertd. This is an Open Access article distributed under the terms of the Creative
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the increased development of obesity.
The aim of this study was to assess the risk of CVD
mortality in relation to obesity and gender [1] in the
general population and [2] separately for those with or
without diabetes at baseline.
Subjects and methods
Study population
This analysis was based on 11 cohorts from the DECODE
(Diabetes Epidemiology: Collaborative analysis Of Diag-
nostic criteria in Europe) study including 45 594 individ-
uals (48.2% women) aged 24–99 at baseline, from four
European countries (Finland, Sweden, Turkey and UK).
Information on weight, height, waist and hip circumfer-
ences, self-reported smoking status, leisure-time physical
activity, and history of diabetes mellitus were available. In
addition, 20 270 individuals (44.7% women) had data on
fasting or 2-h plasma glucose (FPG and 2hPG) from a
75 g oral glucose tolerance test. Individual participant data
from each cohort were sent to the National Institute for
Health and Welfare in Helsinki, Finland for collaborative
data analyses. Studies included were approved by local
ethics committees, and the analysis plan was approved by
the ethics committee of the National Institute for Health
and Welfare, Helsinki, Finland.
Definition of covariates
Height and weight were measured without shoes and with
light clothing. Waist circumference (WC) was measured
midway between the lower rib margin and iliac crest. Hip
circumference was measured at the level of the widest cir-
cumference over the greater trochanters. Body mass index
(BMI) was calculated as weight in kilograms divided by
the square of height in meters. Waist-to-hip ratio (WHR)
and waist-to-height ratio (WHtR) were calculated as waist
circumference divided by hip circumference or height,
respectively. Participants were classified into five cat-
egories: underweight (BMI <18.5 kg/m2), normal weight
(BMI 18.5-24.9 kg/m2), overweight (BMI 25.0-29.9 kg/
m2), obesity (BMI 30.0-34.9 kg/m2) and severe obesity
(BMI ≥35.0 kg/m2), according to the WHO classifica-
tion criteria [36]. Due to the low number of partici-
pants in the underweight category in this study
population, the underweight and normal weight groups
were combined for analysis. Abdominal obesity was de-
fined as the sex-specific top quartile of WC, WHR or
WHtR (WC ≥99 cm, WHR ≥0.97, and WHtR ≥0.57 for
males; WC ≥90 cm, WHR ≥0.85, and WHtR ≥0.56 for
females, respectively). Participants reporting reading,
watching TV, housework, sewing and walking <1 km
daily were defined as physically inactive; all those en-
gaging in higher levels of physical activity were defined
as physically active. Based on responses to the questionnaire,smoking status at baseline was classified into three
categories of never, former and current smokers. Dia-
betes was defined as either a history of diabetes at
baseline or an FPG level ≥7.0 mmol/L and/or a 2hPG
level ≥11.1 mmol/L [37].
Definition of fatal events
Vital status and causes of death were recorded for all par-
ticipants. CVD mortality was defined according to the
International Classification of Disease codes 401–448 (9th
revision) or I10–I79 (10th revision).
Statistical analyses
The absolute CVD mortality rate per 10 000 person-years
of follow-up for each obesity and gender category was cal-
culated. Cox proportional hazards models were used to
estimate hazard ratios (HR) and 95% confidence intervals
(CIs) for CVD mortality, adjusting for baseline smoking
status, leisure-time physical activity and cohort, using
attained age as the timescale and non-obese women as the
reference group. To investigate whether the gender differ-
ence in CVD mortality was different in non-obese from
obese participants, we checked for the interaction between
sex and obesity in the Cox models, using a chi-squared
log-likelihood ratio test. STATA version 11 (StataCorp,
College Station, TX, USA) was used.
Results
Table 1 provides baseline characteristics of the cohorts.
Median follow-up time varied between 2.5 and 21.8 years
in the different cohorts. Lean females were younger, more
abdominally obese and had low prevalence of diabetes,
while obese females were older, less abdominally obese
and had higher prevalence of diabetes at baseline, com-
pared with their respective male counterparts (Table 2).
More men than women were smokers and physically
active. Men tended to have higher mean values of sys-
tolic blood pressure and fasting plasma glucose, and a
worse lipid profile than women, regardless of BMI cat-
egories. Similar characteristics were observed among
non-diabetic individuals (Additional file 1: Table S1).
But diabetic men tended to be older and less physically
active. Similar gender specific baseline characteristics
were observed within the categories of abdominal
obesity defined by sex-specific quartiles of anthropo-
metric measures of WC, WHR and WHtR (Additional
file 1: Table S2).
During the median follow-up of 7.9 years, 945 (4.0%)
men and 339 (1.5%) women died from CVD. Absolute
rates and age- or multivariate-adjusted HRs for CVD mor-
tality are shown across BMI categories or sex-specific
quartiles of anthropometric measures of abdominal obes-
ity (Table 3). Males had higher CVD mortality rates and
higher hazard ratios across BMI categories, and categories
Table 1 Baseline characteristics and follow-up information of the survey participants
Study Number ofparticipants
Age
(years) BMI (kg/m
2) WC (cm) WHR WHtR
Median
follow-up
(years)
No. (%) of
CVD deaths
Men
Finland
FINRISK (1987) 2541 43.8 (11.2) 26.7 (3.7) 92.2 (10.7) 0.90 (0.06) 0.53 (0.06) 21.8 293 (11.5)
FINRISK (1992) 2570 44.3 (11.2) 26.6 (3.9) 93.9 (11.2) 0.92 (0.07) 0.53 (0.07) 16.8 152 (5.9)
FINRISK (1997) 3788 48.6 (13.5) 26.9 (3.9) 94.5 (11.3) 0.93 (0.07) 0.54 (0.07) 11.8 205 (5.4)
FINRISK (2002) 3808 48.0 (13.0) 27.2 (4.1) 95.4 (11.8) 0.97 (0.07) 0.54 (0.07) 6.8 69 (1.8)
Sweden
Northern Sweden MONICA (1986) 671 46.0 (11.4) 25.4 (3.4) 92.4 (9.2) 0.94 (0.05) 0.52 (0.06) 20.5 49 (7.3)
Northern Sweden MONICA (1990) 761 45.0 (11.3) 25.8 (3.3) 91.4 (9.1) 0.93 (0.06) 0.52 (0.05) 16.5 30 (3.9)
Northern Sweden MONICA (1994) 877 49.6 (14.0) 26.2 (3.7) 93.4 (10.1) 0.94 (0.06) 0.53 (0.06) 12.5 37 (4.2)
Northern Sweden MONICA (1999) 869 50.6 (14.3) 26.7 (3.5) 95.3 (9.7) 0.92 (0.07) 0.54 (0.06) 7.4 14 (1.6)
Northern Sweden MONICA (2004) 864 50.9 (14.1) 27.2 (3.9) 96.4 (10.7) 0.96 (0.06) 0.54 (0.06) 2.5 0
Turkey
TARFS (1998–2002) 1580 53.2 (12.4) 26.4 (4.0) 94.3 (11.0) 0.93 (0.07) 0.56 (0.06) 7.9 55 (3.5)
UK
Whitehall II (1991–1993) 5300 49.3 (6.0) 25.1 (3.2) 87.4 (9.2) 0.90 (0.06) 0.50 (0.05) 5.9 41 (0.8)
Total 23 629 48.0 (11.8) 26.4 (3.8) 92.6 (11.0) 0.93 (0.07) 0.53 (0.07) 7.9 945 (4.0)
Women
Finland
FINRISK (1987) 2812 43.7 (11.4) 26.0 (4.9) 79.4 (11.2) 0.78 (0.06) 0.49 (0.07) 21.8 119 (4.2)
FINRISK (1992) 2828 44.0 (11.5) 25.7 (4.9) 80.2 (11.7) 0.79 (0.07) 0.49 (0.08) 16.9 55 (1.9)
FINRISK (1997) 3788 46.1 (12.7) 26.1 (4.9) 81.3 (12.2) 0.80 (0.07) 0.50 (0.08) 11.8 61 (1.6)
FINRISK (2002) 4383 46.6 (13.0) 26.4 (5.0) 83.6 (12.6) 0.84 (0.06) 0.52 (0.08) 6.8 14 (0.3)
Sweden
Northern Sweden MONICA (1986) 685 45.6 (11.1) 25.0 (4.4) 85.3 (12.2) 0.86 (0.07) 0.52 (0.08) 20.5 18 (2.6)
Northern Sweden MONICA (1990) 793 44.8 (11.4) 25.0 (4.4) 79.4 (11.0) 0.81 (0.06) 0.49 (0.07) 16.5 12 (1.5)
Northern Sweden MONICA (1994) 902 49.4 (14.0) 25.8 (4.7) 84.2 (12.4) 0.83 (0.08) 0.52 (0.08) 12.5 16 (1.8)
Northern Sweden MONICA (1999) 900 50.1 (14.1) 26.3 (4.6) 84.9 (11.8) 0.82 (0.07) 0.52 (0.08) 7.5 3 (0.3)
Northern Sweden MONICA (2004) 909 49.7 (13.9) 26.6 (5.1) 86.6 (12.9) 0.85 (0.07) 0.53 (0.08) 2.5 0
Turkey
TARFS (1998–2002) 1619 52.7 (12.3) 28.8 (5.6) 90.7 (12.7) 0.84 (0.08) 0.58 (0.09) 7.9 35 (2.2)
UK
Whitehall II (1991–1993) 2346 50.2 (6.1) 25.7 (4.7) 75.5 (11.7) 0.77 (0.07) 0.47 (0.07) 5.8 6 (0.3)
Total 21 965 46.9 (12.3) 26.2 (5.0) 82.0 (12.6) 0.81 (0.07) 0.51 (0.08) 11.8 339 (1.5)
Abbreviations: BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, CVD cardiovascular disease.
Data are means (standard deviations) or as noted.
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tended to be attenuated in the obese categories. The inter-
action was statistically significant between gender and
WC (p = 0.02), and WHtR (p = 0.01), but not significant
with BMI and WHR (Table 3). For most studies, study-
specific HRs were within 10% of the pooled estimate, al-
though there was heterogeneity by some studies for theHRs of sex-ratio within BMI 25.0-29.9 kg/m2 (I2 = 95.5%,
P <0.05, Additional file 1: Table S3). However, exclusion of
any study in the analysis had little overall influence on the
main results (Additional file 1: Table S4). The finding per-
sisted when the analysis was restricted to individuals with-
out baseline diabetes, but the gender-obesity interaction
was no longer significant in the non-diabetic population
Table 2 Baseline characteristics of participants by body mass index and sex
<25.0 kg/m2 25.0-29.9 kg/m2 30.0-34.9 kg/m2 ≥35.0 kg/m2
M (n=9275) F (n = 10 519) P* M (n = 10 738) F (n = 7142) P* M (n = 3017) F (n = 2962) P* M (n = 599) F (n = 1342) P*
Age (years) 45.6 (11.8) 42.9 (11.7) 0.00 49.0 (11.5) 49.7 (11.7) 0.00 51.3 (11.3) 52.3 (11.5) 0.00 50.6 (11.3) 52.4 (11.1) 0.00
Abdominal obesity (%)†
WC 0.6 1.3 0.00 26.9 24.2 0.00 91.4 79.3 0.00 99.7 98.1 0.01
WHR 5.3 8.6 0.00 27.4 30.1 0.00 64.3 52.6 0.00 85.1 66.0 0.00
WHtR 0.6 1.2 0.00 23.7 23.1 0.35 89.5 81.0 0.00 99.7 99.0 0.17
Diabetes status (%)‡ 0.27 0.00 0.00 0.04
Newly diagnosed
diabetes
11.3 10.2 13.4 16.0 19.5 24.8 24.4 32.6
Known diabetes 3.2 3.2 6.0 5.4 11.6 10.2 17.2 15.0
Smoking status (%) 0.00 0.00 0.00 0.00
Current smokers 25.6 22.1 23.7 17.6 25.3 15.1 25.2 13.5
Former smokers 27.9 17.3 34.6 18.7 38.7 18.7 38.2 18.7
Physically active (%) 83.1 78.6 0.00 80.4 77.7 0.00 73.3 70.7 0.03 61.9 62.1 0.96
SBP (mmHg)§ 127 (17) 124 (18) 0.00 135 (18) 133 (21) 0.00 142 (19) 140 (21) 0.00 147 (20) 145 (22) 0.04
FPG (mmol/L)§ 5.3 (0.9) 5.2 (0.8) 0.00 5.5 (1.1) 5.4 (1.0) 0.00 5.9 (1.5) 5.7 (1.3) 0.00 6.4 (2.2) 5.9 (1.7) 0.00
TG (mmol/L)§ 1.3 (0.9) 1.0 (0.6) 0.00 1.8 (1.2) 1.4 (0.8) 0.00 2.2 (1.5) 1.6 (1.0) 0.00 2.5 (1.9) 1.9 (1.2) 0.00
HDL-C (mmol/L)§ 1.4 (0.4) 1.7 (0.4) 0.00 1.2 (0.3) 1.5 (0.4) 0.00 1.1 (0.3) 1.4 (0.4) 0.00 1.1 (0.3) 1.3 (0.3) 0.00
Total-C (mmol/L)§ 5.7 (1.2) 5.5 (1.2) 0.00 6.0 (1.2) 5.9 (1.3) 0.00 6.0 (1.2) 5.9 (1.2) 0.04 5.9 (1.2) 5.8 (1.2) 0.61
Abbreviations: M male, F female,WC waist circumference,WHR waist-to-hip ratio,WHtR waist-to-height ratio, SBP systolic blood pressure, FPG fasting plasma
glucose, TG triglyceride, HDL-C high-density lipoprotein cholesterol, Total-C total cholesterol.
Data are means (standard deviations) or as noted.
*Difference between men and women.
†The top quartile of WC, WHR or WHtR in women (90 cm, 0.85 or 0.56) and in men (99 cm, 0.97 or 0.57) was used as abdominal obesity group.
‡21 555 individuals with information on diabetes status, including 1285 with known diagnosis of diabetes and 20 270 with available measurement of fasting plasma glucose
and/or 75 g 2-h oral glucose tolerance test (44.7% women).
§45 573 individuals with available measurement of SBP, 20 759 for FPG, 36 834 for TG, 41 808 for HDL-C and 45 353 for Total-C.
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betic individuals diminished especially for non-obese ones.
The findings for BMI categories were not substantially
altered when the analysis was repeated with additional
adjusting for abdominal obesity (Additional file 1: Table
S5). Multivariate adjustment for other CVD risk factors
such as systolic blood pressure, fasting plasma glucose,
triglyceride, high-density lipoprotein cholesterol or total
cholesterol decreased the HRs in each obesity category for
both men and women but the gender difference remained
unchanged (Additional file 1: Table S6). A sensitivity ana-
lysis that excluded the first 5 years of follow-up did not
alter the results (Additional file 1: Table S7).
Discussion
Men had a higher CVD mortality than women across all
categories of anthropometric measures of obesity after
adjusting for age, smoking status, leisure-time physical
activity and cohort. The gender difference diminished
somewhat in obese individuals especially among diabetic
participants.
There is substantial evidence of a gender difference in
cardiac autonomic modulation [2-5], lipid and glucosemetabolism [6-9], sex hormones [4,10-14] and cyto-
kines [15-19], that might explain part of the observed
differences of CVD mortality between women and men.
Besides, males tend to have more fat in the abdominal
region, even among normal weight or non-obese men,
which may be predominantly due to the accumulation
of more visceral fat in males than females during the
puberty [38].
In addition, sex hormones might play important roles
in determining body fat mass and its distribution [11,14],
exert multiple direct and indirect effects on insulin and
glucose homeostasis or on cardiovascular physiology
[4,10,12,13]. Specifically, estrogen increases fat deposition
whereas testosterone inhibits fat deposition, and accord-
ingly, men tend to have less overall body fat than women
[14], however, the distribution differs between the sexes as
discussed below. Women tend to accumulate more sub-
cutaneous fat but less intra-abdominal fat than men prob-
ably due to the effects of estrogen by preventing androgen
effects [39]. Intra-abdominal fat is believed to be the main
pathogenic fat depot that has the clinical relevance to
CVD [40], in particular being more metabolically active
than adipose depots located in the hip, thigh or buttocks
Table 3 Mortality rate per 10 000 person-years and multivariate-adjusted hazard ratios for cardiovascular disease mortality in men and women by body mass index
categories or sex-specific quartiles of anthropometric measures of abdominal obesity
BMI, kg/m2 WC, cm* WHR* WHtR*
<25.0 25.0-29.9 30.0-34.9 ≥35.0 <90 (F)/99 (M) ≥90 (F)/99 (M) <0.85 (F)/0.97 (M) ≥0.85 (F)/0.97 (M) <0.56 (F)/0.57 (M) ≥0.56 (F)/0.57 (M)
No. of CVD deaths
Women 90 107 81 61 173 166 195 144 159 180
Men 241 459 198 47 506 439 555 390 480 465
Mortality rate (95% CI)
Women 7 (6-9) 13 (11-16) 25 (20-31) 45 (34-58) 9 (8-10) 29 (25-34) 10 (9-11) 27 (22–31) 8 (7–10) 32 (27–37)
Men 25 (22-29) 41 (37-45) 63 (54-72) 78 (57-104) 28 (26-31) 67 (61-74) 29 (27-32) 70 (63–77) 26 (24–28) 77 (70–84)
Sex ratio in CVD
mortality rate (M/F)
3.5 3.0 2.5 1.7 3.2 2.3 3.0 2.6 3.2 2.4
Hazard ratios (95% CI)†
Women 1.0 (Reference) 1.0 (0.8-1.3) 1.5 (1.1-2.0) 2.8 (2.1-3.9) 1.0 (Reference) 1.9 (1.5-2.3) 1.0 (Reference) 1.6 (1.3-2.0) 1.0 (Reference) 2.0 (1.6-2.5)
Men 3.1 (2.5-4.0) 3.5 (2.8-4.3) 4.5 (3.5-5.7) 6.5 (4.6-9.3) 3.2 (2.7-3.8) 4.8 (4.0-5.7) 3.0 (2.6-3.6) 4.5 (3.8-5.3) 3.2 (2.7-3.9) 5.1 (4.2-6.1)
Sex ratio in CVD
mortality risk (M/F)
3.1 (2.5-4.0) 3.5 (2.8-4.3) 3.0 (2.3-3.8) 2.3 (1.6-3.4) 3.2 (2.7-3.8) 2.6 (2.1-3.1) 3.0 (2.6-3.6) 2.7 (2.3-3.3) 3.2 (2.7-3.9) 2.6 (2.2-3.0)
Hazard ratios (95% CI)‡
Women 1.0 (Reference) 1.0 (0.8-1.4) 1.6 (1.1-2.1) 2.8 (2.0-3.8) 1.0 (Reference) 1.9 (1.6-2.4) 1.0 (Reference) 1.8 (1.5-2.3) 1.0 (Reference) 2.1 (1.7-2.6)
Men 2.8 (2.2-3.6) 3.1 (2.5-3.9) 3.8 (2.9-4.9) 5.4 (3.8-7.7) 2.9 (2.4-3.4) 4.1 (3.4-5.0) 2.7 (2.3-3.2) 4.2 (3.5-5.1) 3.0 (2.5-3.6) 4.4 (3.6-5.3)
Sex ratio in CVD
mortality risk (M/F)
2.8 (2.2-3.6) 3.0 (2.4-3.7) 2.4 (1.8-3.2) 2.0 (1.3-2.9) 2.9 (2.4-3.4) 2.1 (1.8-2.6)§ 2.7 (2.3-3.2) 2.3 (1.9-2.8) 3.0 (2.5-3.6) 2.1 (1.8-2.5)§
Abbreviations: BMI body mass index, WC waist circumference, WHR waist-to-hip ratio, WHtR waist-to-height ratio, F female, M male, CVD cardiovascular disease, CI confidence intervals.
*The top quartile of WC, WHR or WHtR in women (90 cm, 0.85 or 0.56) and in men (99 cm, 0.97 or 0.57) was used as the abdominal obesity group.
†Hazard ratios (95% CI) from the Cox proportional hazards model using attained age as time-scale.
‡Hazard ratios (95% CI) from the Cox proportional hazards model adjusted for baseline smoking status, leisure-time physical activity, and cohort using attained age as time-scale.
§Significance level = 0.05 for interactions between obesity and gender.
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Table 4 Mortality rate per 10 000 person-years and multivariate adjusted hazard ratios for cardiovascular disease mortality among non-diabetic and diabetic individuals
by sex and body mass index categories or sex-specific quartiles of anthropometric measures of abdominal obesity
BMI, kg/m2 WC, cm* WHR* WHtR*
<25.0 25.0-29.9 30.0-34.9 ≥35.0 <90 (F)/99 (M) ≥90 (F)/99 (M) <0.85 (F)/0.97 (M) ≥0.85 (F)/0.97 (M) <0.56 (F)/0.57 (M) ≥0.56 (F)/0.57 (M)
Non-diabetic (n = 17 056)
Mortality rate (95% CI)
Women 9 (6-13) 14 (10-19) 29 (20-41) 50 (30-76) 12 (9-15) 29 (22-39) 14 (11-17) 24 (17-32) 11 (9-14) 32 (24-41)
Men 26 (21-32) 41 (35-48) 57 (44-73) 45 (18-92) 30 (26-34) 59 (50-71) 31 (27-35) 60 (49-71) 28 (24-33) 66 (56-78)
Sex ratio in CVD mortality
rate (M/F)
2.9 3.0 2.0 0.9 2.5 2.0 2.3 2.5 2.6 2.1
Hazard ratios (95% CI)†
Women 1.0 (Reference) 1.0 (0.7-1.6) 1.8 (1.1-3.0) 3.3 (1.9-5.8) 1.0 (Reference) 1.8 (1.3-2.6) 1.0 (Reference) 1.5 (1.0-2.2) 1.0 (Reference) 2.0 (1.4-2.8)
Men 3.6 (2.4-5.4) 3.9 (2.7-5.7) 4.6 (3.0-7.0) 4.1 (1.8-9.4) 3.3 (2.5-4.3) 4.4 (3.3-5.8) 3.0 (2.3-3.8) 4.1 (3.1-5.4) 3.3 (2.5-4.4) 4.7 (3.5-6.3)
Sex ratio in CVD mortality
risk (M/F)
3.6 (2.4-5.4) 3.7 (2.7-5.3) 2.5 (1.6-3.8) 1.3 (0.5-3.0) 3.3 (2.5-4.3) 2.4 (1.7-3.3) 3.0 (2.3-3.8) 2.7 (1.9-3.9) 3.3 (2.5-4.4) 2.4 (1.8-3.3)
Hazard ratios (95% CI)‡
Women 1.0 (Reference) 1.1 (0.7-1.7) 1.9 (1.2-3.0) 3.3 (1.9-5.8) 1.0 (Reference) 1.9 (1.4-2.8) 1.0 (Reference) 1.8 (1.2-2.6) 1.0 (Reference) 2.0 (1.4-2.9)
Men 3.2 (2.1-4.8) 3.4 (2.3-4.9) 3.9 (2.5-6.0) 3.8 (1.7-8.6) 2.9 (2.2-3.8) 3.8 (2.8-5.1) 2.6 (2.0-3.3) 4.1 (3.1-5.6) 2.9 (2.2-3.9) 4.0 (2.9-5.4)
Sex ratio in CVD mortality
risk (M/F)
3.2 (2.1-4.8) 3.1 (2.2-4.4) 2.1 (1.4-3.2) 1.2 (0.5-2.7) 2.9 (2.2-3.8) 2.0 (1.4-2.7) 2.6 (2.0-3.3) 2.3 (1.6-3.3) 2.9 (2.2-3.9) 2.0 (1.4-2.7)
Diabetic (n = 4499)
Mortality rate (95% CI)
Women 39 (22–63) 52 (36–74) 57 (37–84) 70 (43–407) 40 (28–57) 64 (49–83) 37 (26–51) 73 (55–94) 35 (23–51) 66 (51–83)
Men 54 (36–77) 118 (95–144) 138 (103–182) 146 (80–245) 80 (64–99) 138 (113–167) 89 (72–108) 130 (105–160) 84 (67–105) 128 (105–154)
Sex ratio in CVD mortality
rate (M/F)
1.4 2.3 2.4 2.1 2.0 2.1 2.4 1.8 2.4 1.9
Hazard ratios (95% CI)†
Women 1.0 (Reference) 1.0 (0.6-1.9) 1.0 (0.5-1.8) 1.3 (0.7-2.5) 1.0 (Reference) 1.1 (0.7-1.7) 1.0 (Reference) 1.3 (0.8-1.9) 1.0 (Reference) 1.2 (0.8-1.9)
Men 1.3 (0.7-2.3) 2.2 (1.3-3.8) 2.5 (1.4-4.4) 2.7 (1.3-5.7) 1.8 (1.2-2.7) 2.4 (1.6-3.5) 2.2 (1.5-3.2) 2.4 (1.6-3.6) 2.2 (1.4-3.4) 2.3 (1.5-3.6)
Sex ratio in CVD mortality
risk (M/F)
1.3 (0.7-2.3) 2.2 (1.5-3.3) 2.6 (1.6-4.1) 2.1 (1.1-4.2) 1.8 (1.2-2.7) 2.2 (1.6-3.0) 2.2 (1.5-3.2) 1.9 (1.4-2.7) 2.2 (1.4-3.4) 1.9 (1.4-2.6)
Hazard ratios (95% CI)‡
Women 1.0 (Reference) 1.0 (0.5-1.8) 0.9 (0.5-1.7) 1.0 (0.5-1.9) 1.0 (Reference) 1.2 (0.8-1.8) 1.0 (Reference) 1.3 (0.9-2.0) 1.0 (Reference) 1.3 (0.8-2.1)
Men 1.3 (0.7-2.4) 1.9 (1.1-3.2) 1.9 (1.1-3.5) 1.6 (0.8-3.4) 1.9 (1.2-2.9) 2.1 (1.4-3.2) 2.1 (1.4-3.2) 2.3 (1.5-3.5) 2.2 (1.4-3.6) 2.3 (1.4-3.6)
Sex ratio in CVD mortality risk (M/F) 1.3 (0.7-2.4) 1.9 (1.3-2.9) 2.2 (1.3-3.6) 1.7 (0.9-3.4) 1.9 (1.2-2.9) 1.8 (1.3-2.6) 2.1 (1.4-3.2) 1.7 (1.2-2.4) 2.2 (1.4-3.6) 1.7 (1.2-2.4)
Abbreviations: BMI body mass index,WC waist circumference,WHR waist-to-hip ratio, WHtR waist-to-height ratio, F female, Mmale, CI confidence intervals.
*The top quartile of WC, WHR or WHtR in women (90 cm, 0.85 or 0.56) and in men (99 cm, 0.97 or 0.57) was used as the obesity group.
†Hazard ratios (95% CI) from the Cox proportional hazards model using attained age as time-scale. ‡Hazard ratios (95% CI) from the Cox proportional hazards model adjusted for baseline smoking status, leisure-time physical activity, and
cohort using attained age as time-scale.
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http://www.cardiab.com/content/13/1/144[41]. Clinical studies showed that there was higher intra-
abdominal fat accumulation in men than in women for a
given level of BMI, WC or WHR [42-44]. In contrast,
adult women tend to have a larger hip circumference
than men. This is partly due to a difference in bone
structure of pelvis, but also in subcutaneous fat mass,
that through the metabolically protective physiology of
gluteofemoral subcutaneous fat mass, perhaps by trap-
ping excess fatty acids and preventing chronic expos-
ure to elevated lipid levels, or through a beneficial
adipokine profile (leptin and adiponectin) [45]. It remains
unclear whether CVD risk differs by site of subcutaneous
fat accumulation. In addition, estrogen might also play
a role in the maintenance of glucose homeostasis and
substrate metabolism [46]. Men had significantly higher
fasting and significantly lower post-challenge insulin
levels than women did [8,47], which is not fully explained
by differences in fasting and post-challenge glucose
levels between sexes [47]. Additionally, adults have
tended to show greater insulin resistance in men than
in women [7,9].
Adipose tissue is also a highly active metabolic and
endocrine organ, which expresses and secretes a variety
of bioactive factors including leptin, adiponectin, and
other cytokines [19], which might contribute to the gender
difference in CVD mortality. Women have higher circulat-
ing leptin levels and higher adiponectin levels than men
[15-18]. Hyperleptinemia could be a sign of resistance to
normal leptin signaling regulating food intake and satiety.
This is believed to be a non-physiological state, which has
been associated with an increased risk of diabetes,
hypertension and CVD in men but not in women
[48,49]. Additionally, hypoadiponectinemia has been
found to be associated with an increased risk of both
diabetes and CVD [50,51].
Obesity is associated with increased sympathetic activity
and decreased vagal activity [52,53], hyperglycemia, insulin
resistance [35,54], and is accompanied by chronic low-
grade inflammation [19,55], hypertension and dyslipidemia
[6,56,57], all of which might predispose to CVD. Abdom-
inal obesity, in particular, is also associated with deficiency
of estrogens or testosterone [58,59], although a causal link
still needs to be established [14,60]. Deficiency of estrogens
or testosterone has been consistently found to be associ-
ated with increased risk of CVD [60,61]. Increased leptin
and decreased adiponectin levels were observed in obese
individuals [48,49,62], but the expression of these cytokines
differed between subcutaneous and intra-abdominal fat de-
pots [17,63,64].
Interestingly, the gender difference in CVD mortality
appears to somewhat diminish in obese individuals, al-
though misclassification bias between obese and non-
obese individuals might occur due to the gender difference
of fat distribution, probably enhanced by disturbances ofglucose metabolism. Causes of gender difference in CVD
mortality with obesity are poorly understood. In our
study, the attenuation of the gender difference in CVD
mortality among obese individuals remained after ad-
justment of baseline age or other conventional CVD
risk factors, or among non-diabetic individuals even
when using other measures of abdominal obesity. The
interactions of gender with anthropometric measures
were, however, statistically significant only with WC
and WHtR in the whole study population and not signifi-
cant with any of the anthropometric measures in non-
diabetic individuals. This suggests an effect modification
by diabetes. Studies have indeed shown an attenuation of
gender difference in CVD risk once women getting
diabetes [24-27,29]. Still, there could be other potential
unknown CVD risk factors clustering in obese women
due to their older age that contributed to the increased
CVD risk in obese women.
Since CVD previously has been considered a ‘male dis-
ease’ because of an earlier debut age on the average in
men as compared with women, most epidemiological
studies have been conducted primarily on men, leading to
lesser prevention and treatment efforts in women [65].
Also, obese European women appear to be at greater risk
of psychological dysfunction than obese men probably
due to increased societal pressures on women to be thin
in Europe [66]. In addition, obese women tend to have left
ventricular concentric and eccentric hypertrophy, whereas
obese men have predominantly concentric hypertrophy,
the latter probably being more strongly related to cardio-
vascular mortality than eccentric hypertrophy, a finding
noted recently [30].
Our study was based on several European population-
based or occupational studies, with sufficient power to
investigate the association between obesity indicators
and CVD mortality risk. Yet, limitations of the study
exist. The study does not have data on changes in an-
thropometric measurements before baseline and during
follow-up, which makes it impossible to exclude the pos-
sibility of ‘reverse causation’ [34], a consequence of
underlying diseases before enrolment rather than a cause
of deaths. This was examined by excluding the first five
years of follow-up, and the results were little affected.
Data are based on surveys of Caucasian Europeans, the
results may not be applicable to other ethnic groups or
races due to difference in percentage of body fat across
ethnic groups [67]. Moreover, we do not have data on
changes in anthropometric measurements after meno-
pause. Rapid accumulation of abdominal fat after meno-
pause has been suggested to reduce the gender difference
in body fat distribution [11,68]. In addition, we do not
have information on the use of hormone replacement
therapy, which decreases weight gain and the accumula-
tion of intra-abdominal fat in postmenopausal women
Song et al. Cardiovascular Diabetology 2014, 13:144 Page 8 of 10
http://www.cardiab.com/content/13/1/144[69]. Since this is a collaborative data analysis, certain life-
style variables such as physical activity were recorded dif-
ferently in different studies. Despite the efforts to
“harmonize” variables and to adjust for the different stud-
ies in the data analysis, discrepancies exist. The discrepan-
cies in study design and methodologies have been taken
into account in our data analysis by fitting “study cohort”
into the models as a co-variable, and by making a meta-
analysis based on risk estimate of each single study. The
effect of each study was also examined by removing each
study from the pooled analysis. Exclusion of any study in
the analysis had little overall influence on the main
findings.
In summary, men had higher CVD mortality than
women across all categories of anthropometric measures
of obesity, but this gender difference in CVD mortality
somewhat diminished in obese individuals, which war-
rants further investigation to understand the underlying
mechanism.
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